Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy.
Junxing ChayBeau J FennerEric A FinkelsteinKelvin Yi Chong TeoChui Ming Gemmy CheungPublished in: Eye (London, England) (2021)
Our study shows that combination therapy is good value for money but is likely to increase costs when applied in real-world settings.